AimVion will be a leading company in the field of drug discovery and development. We aim at bringing better treatments to the patients through advancing our novel anti-inflammation technologies and devising new and affordable treatments against autoimmune diseases.

Business model
AimVion wil expand its portfolio of anti-inflammatory drug candidates towards different indication areas including Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). In the short term, the company will achieve this goal through early partnering of its lead compound for Rheumatoid Arthritis.
Our long term business strategy is to develop new treatments for multiple autoimmune diseases internally, up to clinical phase II stage, financed in part by revenue generated from outlicensing of earlier compounds including our current lead for RA, as well as public offering of the company.